Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -85.16% | -88.83% | -90.29% | -92.77% | -69.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -85.16% | -88.83% | -90.29% | -92.77% | -69.55% |
| Cost of Revenue | 1.03% | -57.40% | -74.63% | -85.96% | -89.40% |
| Gross Profit | -67.86% | -91.35% | -91.30% | -92.51% | -94.07% |
| SG&A Expenses | 4.28% | -10.62% | -50.98% | -56.32% | -65.25% |
| Depreciation & Amortization | 4.60% | 55.30% | 210.28% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.43% | -49.24% | -68.41% | -73.29% | -50.70% |
| Operating Income | -75.27% | -861.98% | -441.39% | -187.53% | -164.76% |
| Income Before Tax | 523.09% | 29.39% | -734.95% | -272.76% | -234.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 460.95% | 31.15% | -1,369.45% | -322.07% | -238.22% |
| Earnings from Discontinued Operations | 59.15% | -65.45% | 130.15% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -249.75% | -242.82% | -557.32% | -19.78% |
| Net Income | 234.01% | 83.43% | 63.08% | 57.23% | -566.69% |
| EBIT | -75.27% | -861.98% | -441.39% | -187.53% | -164.76% |
| EBITDA | -80.58% | -2,233.86% | -323.61% | -172.39% | -151.12% |
| EPS Basic | 232.51% | 81.68% | 60.57% | 54.59% | -565.38% |
| Normalized Basic EPS | 8.60% | -36.62% | -13,100.00% | -457.69% | -522.73% |
| EPS Diluted | 232.51% | 81.68% | 60.57% | 54.59% | -565.38% |
| Normalized Diluted EPS | 8.60% | -36.62% | -13,100.00% | -457.69% | -522.73% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |